Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis
Table 3
Whole blood cell distribution and RANKL expression.
Baseline
Follow-up
value
Neutrophils (%)
82 [71–91]
90 [84–091]
0.2662
Neutrophils (×108 cells/L)
12.7 [8.0–15.6]
9.6 [8.4–12.9]
0.2642
RANKL+ neutrophils (%)
22 [3–41]
53 [21–77]
0.0856
RANKL+ neutrophils (×108 cells/L)
1.5 [0.3–4.3]
5.9 [1.8–7.1]
0.1475
Neutrophil RANKL MFI
33.2 [25.5–44.9]
24.1 [21.7–28]
0.0830
T-cells (%)
62 [58–74]
68 [52–72]
0.5265
T-cells (×108 cells/L)
4.2 [2.4–5.2]
3.4 [2.4–11.7]
0.4131
RANKL+ T-cells (%)
6.2 [0.8–24]
6.7 [4.6–15.7]
0.8984
RANKL+ T-cells (×108 cells/L)
0.30 [0.03–1.03]
0.20 [0.16–0.69]
0.7646
T-cell RANKL MFI
49 [41–55]
32 [25–53]
0.2061
B-cells (%)
7.3 [4.8–14]
9.2 [4.9–15.0]
0.7364
B-cells (×108 cells/L)
0.40 [0.18–0.94]
0.44 [0.23–1.51]
0.9658
RANKL+ B-cells (%)
4.7 [2.0–6.7]
14 [3–28]
RANKL+ B-cells (×108 cells/L)
0.02 [0.01–0.06]
0.06 [0.02–1.22]
B-cell RANKL MFI
48 [38–80]
30 [25–63]
Flow cytometry results are shown as median and interquartile range; on granulocytes from whole blood; on the correspondent parent gate (neutrophil, T- or B-cell); on the nongranulocyte cells from whole blood (also called the “monolymph” gate). RANKL: receptor activator of NF-κβ ligand; MFI: median fluorescence intensity (arbitrary units); , . †Remained significant after correction for multiple comparisons.